Immunex Corporation and Genentech, Inc. join forces to develop TRAIL/Apo2L in cancer

SEATTLE and SOUTH SAN FRANCISCO, June 1, 1999- Immunex Corporation (NASDAQ: IMNX) and Genentech, Inc. (NYSE:GNE) announced today that the two companies agreed to jointly develop TRAIL/Apo2L, an entirely new approach to research in the fight against cancer. Pending FDA approval, the companies have also agreed to jointly commercialize the product.

"Combining our world class leadership in science and pharmaceutical development enhances our ability to more efficiently evaluate TRAIL/Apo2L and its potential to fight cancer," said Arthur D. Levinson, PhD, Genentech president and CEO, and Ed Fritzky, Immunex chairman and CEO, in a joint statement. "Should the science and clinical studies prove consistent with the preclinical findings that the molecule has already shown, our companies are poised to move to the next level of development with this new technology."

Immunex and Genentech have each conducted extensive preclinical testing of different forms of TRAIL/Apo2L. TRAIL/Apo2L, also known as TNF-related apoptosis-inducing ligand, appears in animal models to suppress tumor growth and causes remission of tumors, by a direct and specific mechanism known as apoptosis, or programmed cell death. TRAIL/Apo2L binds to at least four distinct receptors found on many tumor cells and signals these cells to destroy themselves through apoptosis. In preclinical research, TRAIL/Apo2L has been shown to cause a wide variety of tumor cells to undergo apoptosis while sparing normal cells. Preclinical studies have not identified significant toxicities from TRAIL/Apo2L administration.

The companies will form a joint steering committee and project team to select a single lead molecule for development, manage the development process, and allocate clinical, manufacturing and marketing responsibilities to each company. Immunex and Genentech each have filed patent applications covering TRAIL/Apo2L and its uses, and Immunex was awarded a patent coveri

Contact: Tim Warner
Immunex Corporation

Page: 1 2

Related biology news :

1. UWs new Cell Systems Initiative welcomes Immunex collaboration
2. Immunex And Wyeth-Ayerst Laboratories Advance Enbrel Into Phase II/III Clinical Trial For Chronic Heart Failure
3. Corporations and environmentalists can be allies to reduce industrys ecological footprint
4. UCSD-Salk Institute awards presented to Christopher Reeve, Dr. Donald Seldin, Genentech, Inc. and Dr. Dennis Slamon
5. East Asian governments urged to harness market forces to improve environment, save money
6. NYAS and Nature Publishing Group join forces
7. Foundations join forces to find a cure or treatment for deadly genetic disease
8. Foundations join forces to finance research for Canavan disease
9. Whats next as biology, math combine forces, reciprocate in discovery
10. Fluid forces within the body help invasive bacteria
11. Disorder forces DNA molecules out of tight spaces

Post Your Comments:

(Date:7/10/2020)... , ... July 09, 2020 , ... Today CJ BIO ... which will share insight on the “fifth taste” phenomenon that is revolutionizing ingredient mixes, ... Umami Advantage will be live on Monday, July 13, 2020 at11:00 AM (CDT) during ...
(Date:7/2/2020)... ... July 02, 2020 , ... ... (MBS) has announced a publication detailing the use of its revolutionary NEXTGENPCR ... chain reaction (RT-PCR) in 16 minutes. The article, titled "Ultra-fast one-step RT-PCR ...
(Date:6/28/2020)... ... June 25, 2020 , ... ... announced that it has entered into a multi-year contract with Merus N.V., ... their translational and clinical research strategy to discover and develop ground-breaking drugs. ...
Breaking Biology News(10 mins):
(Date:9/1/2020)... ... September 01, 2020 , ... ... and diagnostics companies, has announced the placement of Julianne Averill , CPA, ... for leading all financial operations and implementing key business strategies to accelerate Alveo’s ...
(Date:8/12/2020)... ... August 11, 2020 , ... ... engineering firm, is making available for free its new white paper – ... transport simulation testing into today’s biologics licensing application (BLA). In response, Modality ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is ... $3950. With 50 million stem cells total, patients may choose which extremities they would ... for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is ...
(Date:7/31/2020)... ... July 29, 2020 , ... eSource has long been touted as the ... the history of eSource, the reasons it did not take off as quickly as ... source, the industry is moving towards capturing data electronically for clinical trials and then ...
Breaking Biology Technology:
Cached News: